Hepatitis B vaccine immunogenicity in Kerman 12 months infants
Authors: not saved
Abstract:
Introduction: Infection with HBV is the most common chronic viral infection and mortality in children. Prevention of this infection with vaccination is vital. This study was done to compare the antibody level in post hepatitis B vaccination in children with 12 months age. Materials and Methods:This descriptive study was carreid out on healthy 120 children with 12 months age who had notinfected with hepatitis B infection in, kerman Iran during 2014. gender, body weight, birth weight, gestational age were recorded for each child. Hepatitis B antibody level was measured with ELISA method. Data were analyzed using SPSS-16 . Results: Antibody level was high- protective for %81.7 of children , low-responders for %13.3 and no-protective level for %13.3 of children in our study.For % 86.9 children over 2500 kg of birth weight the Antibody level was highly protective incoparison with %57.1 of under 2500 kg of birth weight. This differnce was significant.Ther was no significantly corrolated with gender,bodyweight,gestational age and Antibody level.The family history for hepatitis B infection was negetive for all samples. Conclusion: This study showed that the %95 of children have adequate levels of anti-HBs (≥ 10 IU/L) after vaccination.in addition, immune response was higher in normal birth weight children. Introduction: Infection with HBV is the most common chronic viral infection and mortality in children. Prevention of this infection with vaccination is vital. This study was done to compare the antibody level in post hepatitis B vaccination in children with 12 months age. Materials and Methods:This descriptive study was carreid out on healthy 120 children with 12 months age who had notinfected with hepatitis B infection in, kerman Iran during 2014. gender, body weight, birth weight, gestational age were recorded for each child. Hepatitis B antibody level was measured with ELISA method. Data were analyzed using SPSS-16 . Results: Antibody level was high- protective for %81.7 of children , low-responders for %13.3 and no-protective level for %13.3 of children in our study.For % 86.9 children over 2500 kg of birth weight the Antibody level was highly protective incoparison with %57.1 of under 2500 kg of birth weight. This differnce was significant.Ther was no significantly corrolated with gender,bodyweight,gestational age and Antibody level.The family history for hepatitis B infection was negetive for all samples. Conclusion: This study showed that the %95 of children have adequate levels of anti-HBs (≥ 10 IU/L) after vaccination.in addition, immune response was higher in normal birth weight children.
similar resources
Immunogenicity of hepatitis B vaccine in preterm infants.
OBJECTIVE To determine the immunogenicity of hepatitis B vaccine in preterm infants when the first dose of vaccine is delayed until hospital discharge. METHODS One hundred two preterm infants (23 to 36 weeks gestational age) born to hepatitis B surface antigen-negative mothers were enrolled. Immunization was initiated just before hospital discharge with subsequent doses 1 and 6 months later. ...
full textResponse to the complete hepatitis B vaccine regimen in infants under 12 months of age: a case series.
OBJECTIVES Describing rates of seroconversion and its associated factors in a series of Brazilian infants following the final dose of the vaccine at 6 months of age. METHODS Peripheral blood samples were collected after the third dose of the vaccine for the detection of anti-hepatitis B surface antibodies among infants of 7-12 months of age. We measured the association between seroconversion ...
full textImmunogenicity and safety of an indigenously developed DTPw hepatitis B combination vaccine in Indian infants.
OBJECTIVE To evaluate the safety and immunogenicity of an indigenous hepatitis B, diphtheria, tetanus and B. pertussis tetravalent vaccine (Shantetra) in comparison with Tritanrix HBTM in healthy Indian infants. DESIGN Multicentric, randomized, single blind intention-to-treat study with 12-18 weeks of follow up period. SETTING 5 out patient departments at tertiary care referral centers acro...
full textHepatitis A seroprevalence among infants aged 12 months in Ankara.
Seroprevalence studies in various age groups contribute to a better understanding of hepatitis A infection and response to hepatitis A immunization. Hepatitis A seroprevalence in 12-month-old infants from Ankara was studied. Among 601 healthy infants, overall hepatitis A seropositivity was found to be 23.5%. There were no gender differences in seropositivity (22.6% for male and 24.5% for female...
full textSTUDY ON THE EF FICACY OF RECOMBINANT HEPATITIS B VACCINE IN IRANIAN INFANTS
In order to determine the efficacy of recombinant hepatitis B vaccine in Iranian infants, we analyzed the efficacy of a recombinant hepatitis B vaccine in 115 infants aged 12-24 months born to HBsAg negative mothers who received three doses of HBV Antibody to hepatitis B surface antigen (anti-HBs) was checked after the third dose of the vaccine, 94.8% of the infants had developed protective...
full textSafety and immunogenicity of hepatitis B vaccine ButaNG in adults
Recombinant yeast-derived hepatitis B vaccine manufactured by Instituto Butantan was administered in two groups of adult volunteers (I, II) following two different schedules of immunization. In the first trial (10 &mgr;g doses and 0, 1, 3 months vaccination schedule) 106 individuals completed the full immunization program. The results of seroconversion by age group varied from 70 to 100% and th...
full textMy Resources
Journal title
volume 3 issue 4
pages 0- 0
publication date 2017-11
By following a journal you will be notified via email when a new issue of this journal is published.
No Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023